BioMarin has officially launched kNOWyourDuchenne, a program dedicated to assisting families and clinicians gain access to genetic testing for patients with Duchenne muscular dystrophy (DMD).
This first-of-its-kind program will work to pinpoint specific genetic mutations linked to DMD, which can serve as a guide for healthcare providers to recommend promising treatments currently under development.
“Creating the kNOWyourDuchenne program fits with BioMarin’s mission to provide highly personalized support and services to patients,” said Chuck Bucklar, Vice President Commercial Operations. “Every family with Duchenne has specific needs unique to them, and BioMarin has a decade of experience in tailoring support services based on individual need. The first step to provide support to patients with Duchenne is to make sure that each person with Duchenne is tested and has access to an independent genetic counselor to provide an accurate interpretation of the test results.”
Through the kNOWyourDuchenne program, the company will be providing genetic testing and interpretation at no cost to eligible DMD patients.
“It is important for children and their families with Duchenne muscular dystrophy to know their mutation in order to understand if they qualify for a clinical trial, or to know if they might be candidates for future treatments. Having access to an expert to interpret the genetic test results is critical to determine the most appropriate care,” said Patrick Pallansch, Vice President, Medical Affairs.
To know more about kNOWyourDuchenne and to request access to genetic interpretation and testing services, go to www.kNOWyourDuchenne.com or call 1-844-DUCHENNE (382-4366).
Stay Connected
Sign up for updates straight to your inbox.